Cas:76835-17-1 1-(3,4-Dichlorophenyl)piperazine hydrochloride manufacturer & supplier

We serve Chemical Name:1-(3,4-Dichlorophenyl)piperazine hydrochloride CAS:76835-17-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1-(3,4-Dichlorophenyl)piperazine hydrochloride

Chemical Name:1-(3,4-Dichlorophenyl)piperazine hydrochloride
CAS.NO:76835-17-1
Synonyms:MFCD00190237;n-(3,4-dichlorophenyl)piperazine hydrochloride
Molecular Formula:C10H13Cl3N2
Molecular Weight:267.58300
HS Code:2933599090

Physical and Chemical Properties:
Melting point:217-220°C
Boiling point:370.1ºC at 760 mmHg
Density:N/A
Index of Refraction:
PSA:15.27000
Exact Mass:266.01400
LogP:3.59880

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like MFCD00190237 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,n-(3,4-dichlorophenyl)piperazine hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,n-(3,4-dichlorophenyl)piperazine hydrochloride Use and application,MFCD00190237 technical grade,usp/ep/jp grade.


Related News: The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed. 1-(3,4-Dichlorophenyl)piperazine hydrochloride manufacturer Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business. 1-(3,4-Dichlorophenyl)piperazine hydrochloride supplier In that group, the vaccine slowed brain decline by around 30% in two different clinical and functional tests, Novak said. 1-(3,4-Dichlorophenyl)piperazine hydrochloride vendor The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed. 1-(3,4-Dichlorophenyl)piperazine hydrochloride factory The on-body wear is similar to that of an insulin pump. Unlike insulin pump therapy, however, the investigational system is designed such that users enter only their body weight for the iLet to initialize therapy.